Skip to main content
CCEL logo

CCEL · Cryo Cell International Inc · Financials

Track CCEL — free
$3.82 -0.17 (-4.26%)
Market Cap
$32.65M
Shares
8.06M
Volume · Oct 5 8530 Avg daily vol (3M) 23.09K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$31.57M -1.3%
FY2025 Revenue FY2010–FY2025
Net Income
-$2.43M -704.2%
FY2025 Net Income FY2010–FY2025
Gross Margin
76.63% +1.5pp
FY2025 Gross Margin FY2017–FY2025
Operating Margin
1.53% -9.4pp
FY2025 Operating Margin FY2010–FY2025
Diluted EPS
-$0.30 -700%
FY2025 Diluted EPS FY2010–FY2025
Operating Cash Flow
$5.48M -8.9%
FY2025 Operating Cash Flow FY2010–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
$31.13M $31.57M $31.99M $31.34M $30.34M $28.88M $31.15M $31.82M $29.22M $25.38M $23.13M $21.09M $20.13M $18.99M $17.97M $17.92M $17.76M
$6.87M $7.38M $7.95M $8.39M $8.79M $8.99M $9.66M $10.04M $8.54M $6.72M — — — — — — —
$24.26M $24.19M $24.04M $22.95M $21.54M $19.9M $21.49M $21.78M $20.68M $18.66M — — — — — — —
— 76.63% 75.15% 73.23% 71.02% 68.88% 68.99% 68.46% 70.77% 73.51% — — — — — — —
$311.95K $376.26K $1.24M $1.17M $384.79K $49.87K $23.85K $30.15K $91.85K $41.17K $53.1K $45.78K $64.37K $36.17K $109.64K $184.05K $132.99K
$18.95M $18.22M $18.52M $17.17M $15.58M $14.61M $14.29M $14.89M $15.63M $13.48M $14.72M $12.39M $12.25M $11.37M $14.43M $12.41M $9.49M
$46K $58K $68K $96K $96K $89K $68K $92K $76K $35K $44K $23K $28K $394K $74K $40K —
$975.67K $985.24K $693.85K $1.4M $1.5M $1.04M $372.29K $401.31K $317.33K $131.61K $154.67K $92.11K $171.33K $188.13K $204.15K $361.23K $294.06K
$31.23M $31.08M $28.51M $43.65M $26.31M $24.87M $23.49M $26.75M $24.03M $20.38M $22.69M $18.16M $18.15M $17.29M $19.68M $18.2M $14.42M
-$103.78K $482.39K $3.48M -$12.3M $4.02M $4.02M $7.66M $5.06M $5.19M $5.01M $433.59K $2.93M $1.98M $1.7M -$1.71M -$276.74K $3.35M
— 1.53% 10.88% -39.26% 13.27% 13.91% 24.6% 15.91% 17.76% 19.72% 1.87% 13.91% 9.84% 8.96% -9.52% -1.54% 18.83%
$871.9K $1.47M $4.17M -$10.9M $5.52M $5.06M $8.03M $5.46M $5.51M $5.14M $588.27K $3.03M $2.15M $1.89M -$1.51M $84.49K $3.64M
$1.92M $2.07M $1.86M $1.24M $1.52M $1.38M $1.54M $1.7M $1.55M $1.3M $947.34K $1.3M $1.15M $1.4M $1.02M $1.46M $1.28M
$45.63K — — — — — — — — — — — — — $63.49K $36.91K $26.3K
-$2.44M -$2.82M -$676.16K -$1.06M -$705.52K -$1.41M -$2.62M -$1.67M -$1.57M -$1.38M -$2.91M -$1.96M -$941.2K -$1.35M -$2.55M -$1.42M -$1.26M
— — — — — — — — — — — -$18.82K -$362.88K -$154.05K -$154.56K -$227.02K -$183.41K
-$2.55M -$2.34M $2.8M -$13.36M $3.32M $2.61M $5.04M $3.39M $3.62M $3.62M -$2.48M $949.52K $677.15K $197.02K -$4.42M -$1.92M $1.9M
-$81.55K $92.23K $2.4M -$3.84M $547.54K $527.71K $1.41M $1.1M $4.47M $1.31M -$1.16M -$7.16M $123.53K $169.58K $1.89M $171.94K -$1.56M
-$2.47M -$2.43M $402.1K -$9.52M $2.77M $2.08M $3.62M $2.29M -$854.82K $2.32M -$1.32M $8.11M $553.62K $27.44K -$6.31M -$2.1M $3.46M
— -7.7% 1.26% -30.38% 9.14% 7.21% 11.64% 7.2% -2.93% 9.12% -5.71% 38.43% 2.75% 0.14% -35.11% -11.69% 19.5%
— — — — — — — $2.29M -$554.71K $2.32M -$1.46M $8.28M $553.62K — — -$2M —
USD/shares -$0.29 -$0.30 $0.05 -$1.14 $0.33 $0.26 $0.48 $0.29 -$0.11 $0.33 -$0.16 $0.85 $0.05 $0.00 -$0.56 -$0.18 $0.29
USD/shares -$0.29 -$0.30 $0.05 -$1.14 $0.33 $0.25 $0.45 $0.27 -$0.11 $0.30 -$0.16 $0.83 $0.05 $0.00 -$0.56 -$0.18 $0.29
shares — 8.07M 8.13M 8.34M 8.47M 8.14M 7.54M 7.79M 7.46M 7.06M 8.11M 9.54M 10.18M 10.86M 11.31M 11.76M 11.75M
shares — 8.07M 8.21M 8.34M 8.48M 8.36M 8.14M 8.41M 7.46M 7.65M 8.11M 9.8M 10.43M 10.97M 11.31M 11.76M 11.81M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2012–FY2025: $25.03M in buybacks, $12.92M in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Long-term debt, including current maturities 2026-05-31 USD 8,277,165 10-Q filed 2026-07-15
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current portion of notes payable
USD 195,135
Noncurrent notes payable
USD 8,082,030
Operating lease liabilities 2026-05-31 USD 682,552 10-Q filed 2026-07-15
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current operating lease liabilities
USD 421,888
Noncurrent operating lease liabilities
USD 260,664
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
1.21×
Peer median 0.63×
EV/EBIT
—
P/E (TTM)
—
Peer median 12.40×

Peer medians compare against the 16 similar-size Medical Care Facilities companies (of 56 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Umbilical Cord Blood and Cord Tissue Stem Cell Service $31,382,704 $31,551,550 $30,796,091 $29,771,123 $28,397,401 $30,176,852
Public Cord Blood Banking $129,513 $366,672 $481,148 $461,626 $376,101 $726,554
Prepacyte CB $54,104 $67,884 $66,456 $104,000 $111,400 $244,187

By Product & Service (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Processing and Storage Fees $31,382,704 $31,551,550 $30,796,091 $29,771,123 $28,397,401 $29,547,150
Public Banking $129,513 $366,672 $481,148 $461,626 $376,101 $726,554
Product $54,104 $67,884 $66,456 $104,000 $111,400 $244,187
Licensee and Royalty Income Recognition — — — — — $629,702
Processing and Storage Royalties — — — — — $629,702

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Umbilical Cord Blood and Cord Tissue Stem Cell Service $5,411,691 $4,131,796 -$7,911,698 $5,185,305 $6,362,172 $9,928,886
Prepacyte CB $14,206 -$4,976 $3,188 -$24,493 -$70,335 $60,499
Public Cord Blood Banking -$4,943,503 -$646,536 -$4,395,522 -$1,136,345 -$2,273,604 -$2,327,788

Operating Margin by Segment (%)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Umbilical Cord Blood and Cord Tissue Stem Cell Service 17.2% 13.1% -25.7% 17.4% 22.4% 32.9%
Public Cord Blood Banking -3817% -176.3% -913.5% -246.2% -604.5% -320.4%
Prepacyte CB 26.3% -7.3% 4.8% -23.6% -63.1% 24.8%
Key facts CIK 862692 CUSIP 228895108 Visit website Investor relations